Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Original Article

Protective and curative effects of Livolin forte® on carbon tetrachloride-induced liver damage in Wistar rats

Olaoluwa S. Olukiran, Rufus O. Akomolafe, Kayode D. Bamitale, Akande O. Ajayi, Raphael E. Okonji, Ronald A. Bejide.

Cited by (1)

Objective: Livolin forte® (LIV) is a hepatoprotective drug that is being used in hospitals worldwide in the treatment and management of liver diseases. However, as it appear through the available published literature, the physiological effects of the drug on the liver using a rat model of hepatotoxicity is not yet well established. This study assessed the curative and prophylactic effects of LIV on carbon tetrachloride (CCl4) induced liver damage in rats.
Methods: Twenty-four adult Wistar rats were randomly divided into four groups: group I (normal control) received 0.3 ml/kg/day of propylene glycol for one month; group II (toxicant control) was given 0.7 ml/kg/day of CCl4 dissolved in olive oil (1:1, v/v) orally for 7 days; group III received 5.2 mg/kg/day of LIV for one month followed by CCl4 for one week; group IV received CCl4 for one week and subsequently LIV (5.2 mg/kg/day) was administered for one month. Half of the rats were sacrificed one day after the last treatment, the other half after a 2-week recovery period.
Results: The toxicant control group had significantly higher AST and ALT activities, total bilirubin and lower total protein and GSH levels compared to the normal control rats. Similarly, significant increase in serum activities of AST and ALT were observed in group III compared to the normal control rats a day after the last treatment with CCl4, whereas after the recovery period no significant differences were observed in nearly all the parameters. Moreover, group IV showed no significant differences in the parameters mentioned above compared to the normal control rats a day after the last treatment with LIV and after the recovery period.
Conclusion: The results of this study indicated that LIV was better as a curative agent rather than a prophylactic agent in rats.

Key words: Carbon tetrachloride; Curative; Livolin forte®; Prophylactic; Rat

Full-text options

Full-text Article

Share this Article

Readers of this article also read the following articles
»Neutrophil / Iymphocyte ratio, platelet / Iymphocyte ratio, mean platelet volume and C-reactive protein values in psoriatic arthritis patients
»Status of Sanitation in the Rural Areas of a Health Unit District, Tamil Nadu, India
»Evaluation of Turkey Humoral Immune Response to Avian Influenza and Turkey Rhinotracheitis Viruses Vaccines
»Assessment of Hygiene Habits in Acrylic Denture Wearers: a Cross-sectional Study
»Barriers to treatment adherence of tuberculosis patients: A qualitative study in West Bengal, India
»Toxicological effects of phosphide powder residue in female rats
»A rare cause of neonatal salt wasting: primary pseudohypoaldosteronism
»Validity and reliability of the Turkish Version of the Clinician Rated Severity of Autism Spectrum and Social Communication Disorders Scale
»Prenatal Care Services in Aydin Province
»Contributions of haematological factors to the estimations of Eustrongylides africanus larvae densities Clarias gariepinus and Clarias anguilaris from Bida floodplain of Nigeria
»Carotenoids composition, antioxidant activity and glycemic index
of two varieties of Bactris gasipaes

American Journal of Diagnostic Imaging


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.